* Xoma Corp - Extend maturity date on Xoma’s debt to Novartis from September 2020 to September 2022

* Xoma - Eligible to get low-single-digit royalties on canakinumab sales in cardiovascular indications rising to mid-single-digit royalties in some cases Source text for Eikon: Further company coverage: